Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip Variants
Abstract Evolution of SARS-CoV-2 requires the reassessment of current vaccine measures. Here, we characterized BA.2.86 and the XBB-lineage variant FLip by investigating their neutralization alongside D614G, BA.1, BA.2, BA.4/5, XBB.1.5, and EG.5.1 by sera from 3-dose vaccinated and bivalent vaccinated healthcare workers, XBB.1.5-wave infected first responders, and monoclonal antibody (mAb) S309. We assessed the biology of the variant Spikes by measuring viral infectivity and membrane fusogenicity. BA.2.86 is less immune evasive compared to FLip and other XBB variants, consistent with antigenic distances. Importantly, distinct from XBB variants, mAb S309 was unable to neutralize BA.2.86, likely due to a D339H mutation based on modeling. BA.2.86 had relatively high fusogenicity and infectivity in CaLu-3 cells but low fusion and infectivity in 293T-ACE2 cells compared to some XBB variants, suggesting a potentially differences conformational stability of BA.2.86 Spike. Overall, our study underscores the importance of SARS-CoV-2 variant surveillance and the need for updated COVID-19 vaccines..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 29. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Qu, Panke [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.1101/2023.09.11.557206 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI040825523 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI040825523 | ||
| 003 | DE-627 | ||
| 005 | 20240430104608.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230913s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2023.09.11.557206 |2 doi | |
| 035 | |a (DE-627)XBI040825523 | ||
| 035 | |a (biorXiv)10.1101/2023.09.11.557206 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Qu, Panke |e verfasserin |0 (orcid)0000-0002-0222-365X |4 aut | |
| 245 | 1 | 0 | |a Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip Variants |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Evolution of SARS-CoV-2 requires the reassessment of current vaccine measures. Here, we characterized BA.2.86 and the XBB-lineage variant FLip by investigating their neutralization alongside D614G, BA.1, BA.2, BA.4/5, XBB.1.5, and EG.5.1 by sera from 3-dose vaccinated and bivalent vaccinated healthcare workers, XBB.1.5-wave infected first responders, and monoclonal antibody (mAb) S309. We assessed the biology of the variant Spikes by measuring viral infectivity and membrane fusogenicity. BA.2.86 is less immune evasive compared to FLip and other XBB variants, consistent with antigenic distances. Importantly, distinct from XBB variants, mAb S309 was unable to neutralize BA.2.86, likely due to a D339H mutation based on modeling. BA.2.86 had relatively high fusogenicity and infectivity in CaLu-3 cells but low fusion and infectivity in 293T-ACE2 cells compared to some XBB variants, suggesting a potentially differences conformational stability of BA.2.86 Spike. Overall, our study underscores the importance of SARS-CoV-2 variant surveillance and the need for updated COVID-19 vaccines. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Xu, Kai |e verfasserin |4 aut | |
| 700 | 1 | |a Faraone, Julia N. |e verfasserin |4 aut | |
| 700 | 1 | |a Goodarzi, Negin |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Yi-Min |e verfasserin |4 aut | |
| 700 | 1 | |a Carlin, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Bednash, Joseph S. |e verfasserin |4 aut | |
| 700 | 1 | |a Horowitz, Jeffrey C. |e verfasserin |4 aut | |
| 700 | 1 | |a Mallampalli, Rama K. |e verfasserin |4 aut | |
| 700 | 1 | |a Saif, Linda J. |e verfasserin |4 aut | |
| 700 | 1 | |a Oltz, Eugene M. |e verfasserin |4 aut | |
| 700 | 1 | |a Jones, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Gumina, Richard J. |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Shan-Lu |e verfasserin |0 (orcid)0000-0003-1620-3817 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 29. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:29 |g month:04 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.cell.2023.12.026 |x 0 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2023.09.11.557206 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 29 |c 04 | ||